22825-04-3

Usage

InChI:InChI=1/C16H24O/c1-6-17-12-7-8-13-14(11-12)16(4,5)10-9-15(13,2)3/h7-8,11H,6,9-10H2,1-5H3

Upstream product

• 22824-31-3 5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ol 
• 6223-78-5 2,5-dichloro-2,5-dimethyl hexane 
• 103-73-1 Phenetole 
• 15045-43-9 2,2,5,5-tetramethyltetrahydrofuran 
• 110-03-2 2,5-dimethyl-2,5-hexanediol 
• 627-58-7 2,5-dimethyl-1,5-hexadiene 
• 108-95-2 phenol 
• 1125-78-6 5,6,7,8-Tetrahydro-2-naphthol 
• 75-03-6 ethyl iodide 

Relevant academic research and scientific papers

Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals

Diabetic mammals are treated with compounds that are significantly more efficacious as agonists of RXRβ retinoid receptors than as agonists of RXRα or RXRγ retinoid receptors. The treatment reduces serum glucose and triglyceride levels of the mammals without the undesirable side effects of reducing serum thyroxine levels and a transient increase in serum triglyceride levels Compounds suitable for use in the methods of treatments of the present invention are selected by testing and identifying compounds of selective or specific efficacy as agonists of RXRβ retinoid receptors in preference over RXRα and/or RXRγ retinoid receptors. Novel compounds used in the methods of the invention have Formula 1 where the variables are defined as disclosed in the specification.